Market Closed -
Nasdaq
04:00:00 2024-05-24 pm EDT
|
5-day change
|
1st Jan Change
|
41.16
USD
|
-0.02%
|
|
-12.44%
|
+2.26%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
131.3
|
153.7
|
32.72
|
16.16
|
1,228
|
1,499
|
-
|
-
|
Enterprise Value (EV)
1 |
131.3
|
153.7
|
32.72
|
16.16
|
1,058
|
1,261
|
1,347
|
1,499
|
P/E ratio
|
-3.27
x
|
-4.95
x
|
-1.05
x
|
-0.69
x
|
-17.1
x
|
-16.3
x
|
-26.3
x
|
58.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
33.5
x
|
9.32
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
30.1
x
|
9.32
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-42.4
x
|
-6.32
x
|
-24.3
x
|
309
x
|
FCF Yield
|
-
|
-
|
-
|
-
|
-2.36%
|
-15.8%
|
-4.11%
|
0.32%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
2,977
|
5,308
|
5,320
|
8,159
|
30,499
|
36,411
|
-
|
-
|
Reference price
2 |
44.10
|
28.95
|
6.150
|
1.980
|
40.25
|
41.16
|
41.16
|
41.16
|
Announcement Date
|
3/4/20
|
3/3/21
|
3/31/22
|
3/21/23
|
3/6/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
44.75
|
160.9
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-23.49
|
-36.29
|
-31.53
|
-24.4
|
-41.38
|
-100.1
|
-62.74
|
31
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-140.21%
|
19.27%
|
Earnings before Tax (EBT)
1 |
-30.77
|
-24.64
|
-30.91
|
-24.07
|
-38.99
|
-96.5
|
-61.01
|
39.11
|
Net income
1 |
-30.77
|
-24.64
|
-30.91
|
-24.07
|
-38.99
|
-96.52
|
-61.01
|
9.361
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-136.33%
|
5.82%
|
EPS
2 |
-13.50
|
-5.850
|
-5.850
|
-2.870
|
-2.360
|
-2.530
|
-1.564
|
0.7050
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-24.94
|
-199.4
|
-55.4
|
4.85
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-123.8%
|
3.02%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
51.81%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/4/20
|
3/3/21
|
3/31/22
|
3/21/23
|
3/6/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
3.128
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-3.001
|
-5.773
|
-6.779
|
-6.235
|
-5.61
|
-8.469
|
-8.623
|
-10.38
|
-13.91
|
-23.48
|
-24.09
|
-25.64
|
-27.32
|
-24.3
|
-21.42
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-684.99%
|
Earnings before Tax (EBT)
1 |
-2.828
|
-5.724
|
-6.725
|
-6.132
|
-5.486
|
-8.356
|
-8.475
|
-10.86
|
-11.3
|
-21.4
|
-23.6
|
-25.14
|
-26.82
|
-23.97
|
-21.09
|
Net income
1 |
-2.828
|
-5.724
|
-6.725
|
-6.132
|
-5.486
|
-8.356
|
-8.475
|
-10.86
|
-11.3
|
-21.4
|
-23.6
|
-25.14
|
-26.82
|
-23.97
|
-21.09
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-674.34%
|
EPS
2 |
-0.6000
|
-1.050
|
-0.9000
|
-0.7600
|
-0.5800
|
-0.8800
|
-0.8100
|
-0.9500
|
-0.3300
|
-0.5900
|
-0.6240
|
-0.6480
|
-0.6780
|
-0.6567
|
-0.5733
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/31/22
|
5/10/22
|
8/10/22
|
11/9/22
|
3/21/23
|
5/9/23
|
8/8/23
|
11/7/23
|
3/6/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
170
|
238
|
151
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-24.9
|
-199
|
-55.4
|
4.85
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.02
|
-
|
-
|
-
|
-
|
0.8
|
0.8
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
1.79%
|
-
|
Announcement Date
|
3/4/20
|
3/3/21
|
3/31/22
|
3/21/23
|
3/6/24
|
-
|
-
|
-
|
Last Close Price
41.16
USD Average target price
68.14
USD Spread / Average Target +65.56% Consensus |
1st Jan change
|
Capi.
|
---|
| +2.26% | 1.5B | | +12.30% | 118B | | +12.15% | 106B | | -8.14% | 23.4B | | -0.41% | 22.1B | | -9.28% | 18.34B | | -41.70% | 16.59B | | -15.33% | 15.97B | | +5.80% | 14.03B | | +28.03% | 11.67B |
Bio Therapeutic Drugs
|